Bespoke Digital Events Theatre

FREE TO ATTEND!

Thursday, 13 August 2020
15:00 – 16:00 Singapore Standard Time (SST)

Re-writing the Optimised Clinical Trials Playbook

This bespoke digital theater takes place on Thursday 13th August 15:00-16:00 Singapore Standard Time (SST).   

The clinical trial environment was already evolving at a rapid pace before the presence of COVID-19, but now speed and efficiency are paramount. With a focus toward achieving faster time to market, reducing R&D costs, and increasing clinical trial success rates, various digital tools such as AI, machine learning, telemedicine are quickly becoming the next frontier in clinical studies.  

Alongside the case study sharing of these digital strategies, multiple illustrative examples will be used to present the practical considerations and execution of designing and running various adaptive design strategies, including logistics and impact on clinical operations, data management, and randomization services with focus on implications for statisticians.  

Conducted in the format of a fireside chat, in this session you will be able to gain insights into:  

  • Understanding the impact of today’s environment on clinical trials and their patients  
  • Collaboration and new business models  
  • Clinical study design thinking focus to reduce cost, accelerate speed to market and reduce regulatory burden  
  • Technology innovation for clinical trials – where do we stand?  
  • Critical steps of establishing an effective digital strategy  
  • Case study sharing and Q&A  

The Expert Panelists:

Moderator

spk-chen-guang

Dr. Chen Guang
Consultant and Clinical Diagnostics Technologist
Stronghold Diagnostic Lab – A*STAR, Singapore

Dr. Chen Guang obtained his Ph.D. in Coronavirology from National University of Singapore and has worked in different areas of bio pharmacology. He specialised in clinical research at Duke-NUS Graduate Medical School and Singapore General Hospital, and also has experience in the discovery and development phase at Simcere Pharmaceutical (an NYSE listed company); Dr. Chen is involved in biopharma investment and management. Dr. Chen is currently working on large scale diagnosis lab on COVID-19 at ASTAR.

Panelist

spk-harish-dave

Dr. Harish Dave
Co-founder and Chief Medical Officer, AUM Biosciences, Singapore

A Board-certified oncologist and hematologist with more than 35 years of experience, Dr. Harish Dave has conducted over 100 studies in hematology, oncology and transplantation. He has extensive experience in managing regulatory authorities including successful submission of over 50 INDs. Harish has also structured and executed a private equity Novaquest–sponsored strategic virtual drug development collaboration between Quintiles and Eisai, and has held various senior management positions at IQVIA, George Washington University Medical Center and VA Medical Center in Washington.

Panelist

spk-tam-c-nguyen

Dr. Tam C. Nguyen
Deputy Director of Research, St. Vincent’s Hospital Melbourne, Associate Professor, Melbourne Medical School, Adjunct Associate Professor, RMIT University, Australia

Associate Professor Tam Nguyen PhD MBA FRSPH FAIM MAICD is the Deputy Director of Research at St Vincent’s Hospital Melbourne responsible for research strategy, research business development and research administration. Tam leads a dynamic team dedicated to providing innovative solutions to facilitate health and medical research, which includes the Research Valet® Service, a rapid IRB service. His team leads the sector initiative in building the Victorian Clinical Trials Gateway™, a web portal with the support of the Victorian government aiming to attract new clinical trials to the state and Australia.

Panelist

spk-arnold-chan

Dr. K. Arnold Chan
Director of Clinical Trial Center
National Taiwan University Hospital, Taiwan

Dr. Chan is a physician epidemiologist with more than 20 years of global research experience in academia and private sector, primarily on evaluation of pharmaceutical agents and vaccines. He has served on the faculty at National Taiwan University and Harvard School of Public Health, and returned to his alma mater (National Taiwan University) in 2013.

He has extensive experience in managing research organization and complex human research projects. In addition to scientific research, he has provided consulting input to Taiwan Food and Drug Administration and related health authority for more than 20 years. Dr. Chan has authored or co-authored more than 100 peer-reviewed articles on pharmacoepidemiology and clinical epidemiology. Along with Professor Abraham Hartzema and Professor Hugh Tilson, Dr. Chan co-edited one of the two widely used English textbook on pharmacoepidemiology.